Trial Profile
A Two-Stage, Open-Label Phase 2 Study of Pracinostat and Azacitidine in Patients With IPSS-R High and Very High Risk Myelodysplastic Syndromes Previously Untreated With Hypomethylating Agents
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Mar 2022
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Pracinostat (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Helsinn Healthcare SA
- 04 Feb 2022 Status changed from completed to discontinued.
- 12 Feb 2021 Status changed from active, no longer recruiting to completed.
- 21 Jun 2020 Results assessing the safety and efficacy outcomes in the overall patient population presented at the 25th Congress of the European Haematology Association